Quantcast

Latest ondansetron Stories

2011-07-11 07:33:00

WARREN, N.J., July 11, 2011 /PRNewswire/ -- MonoSol Rx, a specialty pharmaceutical company and the developers of the PharmFilm® technology platform, in collaboration with APR Applied Pharma Research s.a. of Switzerland ("APR"), announced today that its FDA-approved anti-emetic Zuplenz (Ondansetron) oral soluble film is available for licensing to new commercial partners. The Company made the strategic decision to reacquire the commercial rights to Zuplenz from Strativa...

2011-06-16 12:17:18

People seeking help for their alcohol or other drug problems enter treatment with very different levels of motivation to change. Differences in motivation appear to make a critical difference in which patients seek, comply with, and complete treatment. Findings from a study of the extent to which motivation and self-efficacy "“ the confidence to resist temptation and to abstain from drinking "“ changed during treatment, and the degree to which these variables affected drinking...

2011-04-04 07:10:00

WARREN, N.J., April 4, 2011 /PRNewswire/ -- MonoSol Rx, the developers of PharmFilm® technology and a drug delivery company specializing in proprietary pharmaceutical film products, today announced that it has been granted U.S. patent No. 7,897,080 from the United States Patent and Trademark Office (USPTO). The patent provides intellectual property protection for the Company's methods of pharmaceutical film preparation along with the incorporation of specific drugs and...

2011-03-16 15:05:00

POINT RICHMOND, Calif., March 16, 2011 /PRNewswire/ -- Transcept Pharmaceuticals, Inc. (Nasdaq: TSPT), a specialty pharmaceutical company focused on the development and commercialization of proprietary products that address important therapeutic needs in the field of neuroscience, today announced financial results for the three and twelve months ended December 31, 2010. Transcept reported cash, cash equivalents and marketable securities of $68.0 million at December 31, 2010, and...

2011-03-14 06:35:00

POINT RICHMOND, Calif., March 14, 2011 /PRNewswire/ -- Transcept Pharmaceuticals, Inc. (Nasdaq: TSPT) today announced the first patient has been enrolled in a Phase 2 clinical study to evaluate TO-2061 as an adjunctive treatment for obsessive compulsive disorder (OCD) in patients who have responded inadequately to currently approved treatments. OCD affects 1 to 2 percent of the United States adult population and can significantly impair the lives of patients and their families....

2010-10-13 13:22:10

Press release from PLoS Medicine In research published this week in PLoS Medicine, Stephen Freedman (University of Toronto) and colleagues performed a cost analysis of the emergency department administration of oral ondansetron to children with dehydration and vomiting secondary to gastroenteritis and found that this treatment could provide substantial economic, as well as clinical, benefit. The researchers analyzed the costs of the administration of oral ondansetron in both the US and...


Word of the Day
endocarp
  • The hard inner (usually woody) layer of the pericarp of some fruits (as peaches or plums or cherries or olives) that contains the seed.
This word comes from the Greek 'endon,' in, within, plus the Greek 'kardia,' heart.
Related